Singapore, Sept. 3 -- PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced that the US Food and Drug Administration (FDA) has approved BESREMi(R) (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades.

BESREMi has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. The ET approval expands the BESREMi product label, which has been commercially available for the treatment of adults with polycythemia vera (PV).

This approval marks a major milestone for people living with...